Hepatic steatosis associates with leukopoietic activity and atherosclerotic inflammation: mechanistic insights into cardiovascular risk.

Prognostic value of non-alcoholic fatty liver disease, pericoronary fat attenuation index and computed tomography-derived fractional flow reserve in diabetic patients with suspected coronary artery disease.

CCTA-quantified pericornary inflammation and lipoprotein (a): Combined predictive value in non-obstructive CAD.

Type D personality and metabolic syndrome severity jointly predict 2-year MACE after acute coronary syndrome: A prospective cohort study.

Clinical and Technical Predictors of Adverse Cardiovascular Events Following Coronary Lithotripsy in the BENELUX-IVL Registry.

Clinical profile and long-term outcomes of chest pain patients with coronary microvascular dysfunction from the emergency department - results from the Yale-CMD registry.

Impact of Postoperative Anemia and Transfusion in Patients Undergoing Complex Endovascular Aortic Aneurysm Repair.

Prognostic value of non-invasive endothelial function index in emergency department patients with undifferentiated chest pain.

Percutaneous Coronary Intervention for Acute Coronary Syndrome in Young Adults on Dialysis: Insights From Houston Methodist Young ACS-PCI Registry.

One-Year Outcomes in PAD Patients With Elevated Lipoprotein(a): A Propensity-Matched Analysis.

Objective Long-term uric acid exposure as an independent risk factor for cardiovascular disease remains unclear. This study investigated whether or not the running average serum uric acid (Ra-SUA) value measured after percutaneous coronary intervention (PCI) could be associated with the occurrence of subsequent cardiovascular events. Methods The clinical records of 1,761 patients who underwent successful PCI were retrospectively examined. The Ra-SUA values were calculated by adding consecutive SUA values and dividing them by the number of measurements. Based on the Ra-SUA value during an observation period of up to 10 years after PCI, the patients were divided into 3 groups based on the Ra-SUA: >7.0, 5.5-7.0, and ≤5.5 mg/dL. Among these groups, the incidence of major adverse cardiac events (MACEs) was investigated. Furthermore, patients with Ra-SUA ≤5.5 mg/dL were further classified into 3 groups according to Ra-SUA values to investigate the association with the incidence of MACEs. MACEs were defined as coronary-related death, nonfatal myocardial infarction, and new coronary stenosis of non-culprit lesions. Results A Kaplan-Meier analysis demonstrated that the incidence of MACEs was significantly higher in patients with Ra-SUA >7.0 mg/dL than in the other groups. A multivariate analysis indicated that the Ra-SUA value was significantly correlated with the incidence of MACEs. However, patients with Ra-SUA <4.0 mg/dL had an increased incidence of MACEs compared with patients with Ra-SUA 4.0-5.0 mg/dL. Conclusion High Ra-SUA values may be a predictor of increased recurrence of cardiovascular disease after PCI. There may also be a J-curve association between the incidence of MACEs and Ra-SUA values.

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis.

Impact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes.

Transcatheter versus surgical treatment in aortic stenosis with coronary artery disease: A meta-analysis of time-to-event data on 162,305 patients.

The Clinical Impact of Intravascular Imaging-Guided Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with High Thrombus Burden.

Comparative Effectiveness of Prasugrel Versus Ticagrelor in Dialysis-Dependent End Stage Renal Disease Patients Undergoing Percutaneous Coronary Intervention.

Immature platelet fraction in cardiology.

Preoperative use of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors and adverse outcomes after liver surgery: A Nationwide propensity score-matched study.

Cystatin C in atherosclerotic cardiovascular disease.

Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients.